187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)
Rupert Bartsch(Universitätszahnklinik Wien), Matthias Preusser(Medical University of Vienna), A.M. Starzer(Medical University of Vienna), B. Rottenmanner(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Anna S. Berghoff(Medical University of Vienna), Julia Furtner(Medical University of Vienna), C Singer(Medical University of Vienna), Kathrin Strasser‐Weippl(Otto Wagner Hospital), Daniel Egle(Innsbruck Medical University), Maximilian Marhold(Medical University of Vienna), C. Minichsdorfer(Medical University of Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), B. Aretin(Universitätszahnklinik Wien), H. Forstner(Medical University of Vienna), Georg Pfeiler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Thorsten Fuereder(Medical University of Vienna), Mona Hirdler(Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas), H. Rumpold(Kepler Universitätsklinikum)
Cited by 15
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
|Annals of Oncology|2017|634